Study of autoimmune blistering diseases and their severity measures
Official title: Prevalence and Clinical Severity of Autoimmune Blistering Diseases
Run by University of Pennsylvania · NCT02753777 · Data updated 2026-11-12
This study is testing how well certain measures of disease severity work for people with autoimmune blistering diseases to see how they relate to quality of life.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 150 (estimated) |
| Sponsor | University of Pennsylvania Academic / other |
| Locations | 3 sites (Philadelphia, Pennsylvania and 2 other locations) |
| Status | Recruiting |
| Started | April 2016 |
| Main results expected | January 2, 2030 |
| Study ends | January 2, 2030 |
| Registry record updated | March 30, 2026 |
| Trial ID | NCT02753777 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults over 18 years diagnosed with pemphigus vulgaris, pemphigus foliaceus, or bullous pemphigoid.
✕Probably not a fit
Patients under 18 years old or those without a diagnosis of pemphigus or pemphigoid diseases will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study focuses on autoimmune blistering diseases such as pemphigus vulgaris, pemphigus foliaceus, and bullous pemphigoid. It aims to validate disease severity measures, specifically the Pemphigus Disease Area Index (PDAI) and the Bullous Pemphigoid Disease Area Index (BPDAI), by comparing them with other established severity measures. Participants will also assess their quality of life and may contribute blood samples for further research. The goal is to enhance the understanding of disease severity and its impact on patients' lives.
Why it matters
Potential benefit: If successful, this study could lead to improved assessment tools for disease severity, ultimately enhancing treatment strategies for patients with autoimmune blistering diseases.
How similar studies have gone: Other studies have shown success in validating disease severity measures in similar autoimmune conditions, indicating a promising approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Gender/Age: Males or females above 18 years old * Diagnosis: pemphigus vulgaris, pemphigus foliaceus, bullous pemphigoid * Subjects able to give informed consent Exclusion Criteria: * Patients who are under age 18 years. * Patients without pemphigus or pemphigoid diseases * Penn employees * Penn students * Cognitively impaired persons
Where it's running
-
Hospital of the University of Pennsylvania, Department of Dermatology
Philadelphia, Pennsylvania, United States Recruiting -
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania, United States Recruiting -
University of Pennsylvania, Department of Dermatology
Philadelphia, Pennsylvania, United States Recruiting
Study contacts
- Study coordinator: Victoria P Werth, MD
- Email: werth@pennmedicine.upenn.edu
- Phone: 215-615-2940
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
CD19 CAR-T therapy for refractory pemphigus vulgaris
This study tests autologous CD19 CAR-T cells in adults with moderate-to-severe, treatment-refractory pemphigus vulgaris to see if it is safe and may reduce disease activity.
-
Evaluating the safety and efficacy of Rituximab combined with AB-101 for autoimmune diseases
This study is testing if combining a new treatment called AB-101 with rituximab can safely help adults with certain autoimmune diseases feel better.
-
Investigating a new cell therapy for pemphigus vulgaris
This study is testing a new cell therapy for people with pemphigus vulgaris who haven't found relief with standard treatments to see if it can help them feel better.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.